AstraZeneca Crestor Ad Defends Safety, Re-Asserts Superiority Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
"A medication can be more effective and just as safe," the ad maintains. AstraZeneca cites FDA's response to safety reviewer's claim that Crestor is one of five drugs with unresolved safety issues.
You may also be interested in...
Public Citizen Takes Aim At Crestor DTC Ads Defending Statin's Safety
AstraZeneca's newspaper ads and website contain "false and/or misleading statements about the FDA's current opinion about Crestor," Public Citizen says in letter to Acting Commissioner Crawford. Agency is urged to stop the company's advertising campaign.
Public Citizen Takes Aim At Crestor DTC Ads Defending Statin's Safety
AstraZeneca's newspaper ads and website contain "false and/or misleading statements about the FDA's current opinion about Crestor," Public Citizen says in letter to Acting Commissioner Crawford. Agency is urged to stop the company's advertising campaign.
Crestor, Serevent Are Among Problem Drugs Cited By FDA Safety Reviewer
FDA Office of Drug Safety personnel will be publishing a paper on statins and rhabdomyolysis in an upcoming issue of the Journal of the American Medical Association, Associate Director for Science David Graham told the Senate Finance Committee during a Nov. 18 hearing on Merck's withdrawal of Vioxx